Bringing the fundamentals into focus…
Back to Rigel Pharmaceuticals, Inc.
How Rigel Pharmaceuticals, Inc. stacks up
RIGL · against 488 other Healthcare companies of similar size
Valuation
90/ 100
Near the top of its peers.
Ranked #47 of 489 · scores higher than 90% of peers
Bars: peers in each 10-point band of the valuation score51 peers with a valuation score of 90–100, including RIGL · Click a bar to see the companies
Why valuation scores 90?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its earnings yield and EBITDA yield, which are stronger than most Healthcare peers.
- Free cash flow yield is close to the peer norm. Free cash flow yield: 1.0% vs peer median 0.0%
- more operating profit (EBITDA) for the company's total value: stronger than 81% of peers. EBITDA yield: 10.4% vs peer median 4.0%
- higher earnings for the price paid: stronger than 99% of peers. Earnings yield: 35.3% vs peer median 1.5%
Metric by metric
Position: dot = RIGL, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | RIGL | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 477 reported | 34.6% | 1.1% | 100% | 30% | |
| EBITDA yieldHigher is better · 495 reported | 10.3% | 4.1% | 80% | 50% | |
| Free cash flow yieldHigher is better · 210 reported | 1.0% | -2.7% | 67% | 20% | |
| Book yieldHigher is better · 486 reported | 46.7% | 41.6% | 56% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around RIGL| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 12.9B HKD (≈$1.7B) | 99 | 83 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 226.3B JPY (≈$1.5B) | 99 | 77 | |
| 1 | 14.8B MXN (≈$800M) | 99 | 61 | |
| 47 | 7.4B HKD (≈$949M) | 90 | 49 | |
| 47 | 6.3B CNY (≈$887M) | 90 | 52 | |
| 47 | 5.4B CNY (≈$751M) | 90 | 71 | |
| 47 | 78.6B JPY (≈$535M) | 90 | 74 | |
| 47 | 913M USD | 90 | 77 | |
| 52 | 5.3B CNY (≈$748M) | 89 | 61 | |
| 52 | 5.2B CNY (≈$725M) | 89 | 66 | |
| 52 | 4.8B CNY (≈$677M) | 89 | 67 | |
| 52 | 4.3B CNY (≈$601M) | 89 | 63 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score